These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 26743753

  • 1. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM, Lee SJ, Kim CG, Chung EJ, Koh HJ.
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ, Koh HJ.
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [Abstract] [Full Text] [Related]

  • 4. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y, Shimada H, Mori R, Tanaka K, Yuzawa M.
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, Yoshida S, Ishibashi T, Sonoda KH.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N, Dirani A, Butel N, Fardeau C, Bodaghi B, Ingram A, Lehoang P.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
    Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Jan; 33(10):2126-32. PubMed ID: 23609123
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB, Simunovic MP, Vandiver L, Aragon AV, Ysasaga JE.
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.